

Article

Co-Occurrence of Differentiated Thyroid Cancer and Second Primary Malignancy: Correlation with Expression Profiles of Mismatch Repair Protein and Cell Cycle Regulators

Chih-Yi Liu ^{1,2}, Ching-Shui Huang ^{3,4}, Chi-Cheng Huang ^{5,6}, Wei-Chi Ku ², Hsing-Yu Shih ³ and Chi-Jung Huang ^{7,8,*}

¹ Division of Pathology, Sijhih Cathay General Hospital, New Taipei City 221, Taiwan; cyliu@cgh.org.tw

² School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City 221, Taiwan; 089052@mail.fju.edu.tw

³ Division of General Surgery, Department of Surgery, Cathay General Hospital, Taipei 106, Taiwan; cshuang@cgh.org.tw (C.-S.H.); d6200@cgh.org.tw (H.-Y.S.)

⁴ School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan

⁵ Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei 1121, Taiwan; cchuang29@vghtpe.gov.tw

⁶ School of Public Health, College of Public Health, National Taiwan University, Taipei 100, Taiwan

⁷ Department of Medical Research, Cathay General Hospital, Taipei 106, Taiwan

⁸ Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan

* Correspondence: aaronhuang@cgh.org.tw

Citation: Liu, C.-Y.; Huang, C.-S.; Huang, C.-C.; Ku, W.-C.; Shih, H.-Y.; Huang, C.-J. Co-Occurrence of Differentiated Thyroid Cancer and Second Primary Malignancy: Correlation with Expression Profiles of Mismatch Repair Protein and Cell Cycle Regulators. *Cancers* **2021**, *13*, 5486. <https://doi.org/10.3390/cancers13215486>

Academic Editor: Charles H. Lawrie

Received: 27 September 2021

Accepted: 29 October 2021

Published: 31 October 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

Simple Summary: Although the incidence of thyroid cancer is increasing, improvements in treatment have resulted in more patients being confirmed to have a second primary cancer. However, studies on potential biomarkers for predicting the risk of second primary malignancy are extremely limited. Therefore, our objective was to establish molecular biomarkers for the risk prediction of second primary malignancy using routinely collected formalin-fixed paraffin-embedded tissue specimens. Our results suggest that the deficient mismatch repair phenotype, the expression of pRb, and the lack of CDK4 or CDK6 are significantly associated with co-occurrence of nonthyroid malignancy. The predictive value of these immunohistochemical profiles for the co-occurrence of nonthyroid malignancy was also assessed. The combined evaluation of a four-biomarker signature model may provide the most important predictive innovation. Our study proposes the first tissue-based screening tool for risk stratification and further active surveillance in patients with thyroid cancer.

Abstract: Some patients with thyroid cancer develop a second primary cancer. Defining the characteristics of patients with double primary cancers (DPCs) is crucial and needs to be followed. In this study, we examine molecular profiles in DPC. We enrolled 71 patients who received thyroid cancer surgery, 26 with single thyroid cancer (STC), and 45 with DPC. A retrograde cohort was used to develop immunohistochemical expressions of mismatch repair (MMR) proteins and cell-cycle-related markers from tissue microarrays to produce an equation for predicting the occurrence of DPC. The multivariate logistic model of 67 randomly selected patients (24 with STC and 43 with DPC) identified that the expression of deficient MMR (dMMR) (odds ratio (OR), 10.34; 95% confidence interval (CI), 2.17–49.21) and pRb (OR, 62.71; 95% CI, 4.83–814.22) were significantly associated with a higher risk of DPC. In contrast, the expression of CDK4 (OR, 0.19; 95% CI, 0.04–0.99) and CDK6 (OR, 0.03; 95% CI, 0.002–0.44) was significantly associated with a lower risk of DPC. Collectively, dMMR, pRb, CDK4, and CDK6 have a sensitivity of 88.9% (95% CI, 75.1–95.8) and a specificity of 69.2% (95% CI, 48.1–84.9) for occurrence of DPC in all 71 patients. This is the first report to demonstrate the molecular differentiation of STC and DPC. Overall, the integral molecular profile performed excellent discrimination and denoted an exponential function to predict the probability of DPC.

Keywords: thyroid neoplasms; neoplasms; second primary; neoplasms; multiple primary; immunohistochemistry; DNA mismatch repair; cell cycle

1. Introduction

Thyroid cancer is the most common type of endocrine-related malignancy. Follicular-derived or differentiated thyroid cancer (DTC) encompasses 95% of all thyroid malignancies [1,2]. In general, patients with DTC have excellent survival rates, but the prognosis highly depends on the molecular and pathological characteristics of the tumor. The molecular etiology of thyroid cancer is not fully understood. Specific genetic mutations, such as *BRAF*^{V600E}, are associated with more than 70% of papillary thyroid carcinomas (PTC) [1,2]. Molecular characterization can provide valuable information to refine tumor risk stratification. Together with a prognostic role in DTC, the presence of molecular alterations can also guide targeted therapies. Therefore, a better understanding of the genetic and biologic aspects of DTC will contribute to early diagnosis and result in effective therapies and better survival outcomes.

Prolonged survival has resulted in an increased chance of nonthyroid malignancies in thyroid cancer patients, reported in several cancer registry and epidemiological studies [3–18]. The risk of developing thyroid cancer is also elevated after a variety of first primary adult cancers, but it is not clearly related to treatment [19–22]. Among Western populations, large cohort studies have shown up to 30% increase in second primary malignancies, as well as increased risks of thyroid cancer after various primary cancers [13,15,17]. In Asian countries, thyroid cancer is associated with a high rate of co-occurrence of nonthyroid malignancies [7,8]. The risk of developing second cancers after primary thyroid cancer varies from 10% to 150% depending on different types of cancer [18]. According to a population study in Taiwan, thyroid cancer is associated with a 33% risk increase for a second cancer [10]. There are sites of second cancers in the Asian population that are distinctive from those in Western populations, suggesting that genetic predisposition or environmental factors may play a role [10]. Furthermore, the co-occurrence of two primary cancers could account for 18.7% of all deaths in patients with thyroid cancer and impose a negative impact on overall survival [11]. This suggests that an increase in the incidence of double primary cancer (DPC) could be the most important late effect that occurs in patients treated for this disease.

Although several explanations for the observed elevated secondary cancer rates have been proposed, it is hypothesized that the increased risk of DPC may be related to a genetic predisposition or treatment-related complication [4–6,8,9,13,14,23]. Possible explanations also include active posttreatment surveillance, common environmental factors, and dietary factors [11]. In a large-scale multinational study, significantly elevated risks were observed for many specific cancers, including salivary gland, pharynx, stomach, small intestine, colorectum, bone, soft tissue sarcoma, non-melanoma of the skin, female breast, prostate, kidney, brain, adrenal gland, non-Hodgkin lymphoma, and leukemia [15]. Elevated risks of second primary thyroid cancer were also demonstrated following various specific cancers [15]. For Asian populations, there was a greater risk of developing major salivary gland, nasopharyngeal, lung, thymus, breast (female), bladder, and brain cancers, and lymphomas after diagnosis with thyroid malignancies [7,10]. The risk of a second cancer was highest within the first 5 years of thyroid cancer diagnosis and in younger patients according to a population-based study conducted in Taiwan [10]. Therefore, clinicians should maintain a high index of suspicion for the second primary after treatment for thyroid cancer.

It is important to recognize the characteristics of patients with multiple primary malignancies to detect and appropriately treat the second primary malignancy as early as possible. Although significant progress has been made in defining various molecular subtypes of thyroid cancer, the exact underlying molecular mechanism of DPC is still poorly

understood. To date, very few studies have focused on the biomarker discovery aspect of DPC, and so far none has been successfully translated into clinics [24–26]. On the basis of our advances in understanding of carcinogenesis and knowledge of the expression of cell-cycle-related markers and the status of microsatellite instability (MSI), we can potentially develop predictive biomarkers of cancer treatment. However, comprehensive biomarker expression profiles in a large cohort of patients are difficult to obtain due to the complexity of these analyses if performed using conventional full tissue sections. In the present study, we used tissue microarray technology (TMA) combined with immunohistochemical analysis to define the importance of altered expression of these biomarkers in patients with DPC. Molecular profiles in patients with single thyroid cancer (STC) were identified and compared with the DPC group. This study explored associations between the expression of cell-cycle regulatory proteins, mismatch repair (MMR) proteins, and clinical features. The aim was then to establish molecular biomarkers for the prediction of SPC risk using routinely collected formalin-fixed paraffin-embedded tissue specimens.

2. Materials and Methods

2.1. Patients and Histopathology

This study was carried out in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Cathay General Hospital, which granted exemption of informed consent for tissue procurement through the Cathay General Hospital Biobank after an anonymous unlinked process (IRB no.: CGH-P108136, 28 February 2020; Biobank no.: HBKEC-20200928-1).

Patients in the study were obtained from a retrospective search. The examined samples were obtained from archived tissue collections of differentiated thyroid cancer, diagnosed between 1995 and 2010. Clinical information, including age, sex, procedure to obtain the specimen, treatment modality, and follow-up information, was obtained from the biobank database. All samples examined in this study were formalin-fixed paraffin-embedded (FFPE) samples of thyroid cancer.

Patients with a second cancer in organs other than the thyroid were enrolled (double primary cancer (DPC), $n = 45$), and those without available FFPE tissue samples were excluded. To compare the characteristics between the single thyroid cancer (STC) and DPC groups, the STC group was selected from thyroid cancer patients who were not diagnosed with prior or subsequent nonthyroid cancers during the follow-up period ($n = 26$). A total of 71 patients were enrolled in this study and all their available histological slides were reviewed to confirm the diagnosis of DTC. Then, 67 patients (24 with STC, 13 papillary carcinoma and 11 follicular carcinoma; 43 with DPC, 35 papillary carcinoma and 8 follicular carcinoma), randomly selected from these 71 patients, served as cases to establish the predictive model. The median age of these 67 patients (12 men and 55 females) was 52 years (range, 27 to 82 years). The prediction of the primary model derived from 67 patients was used to check the probability of DTC of all 71 patients.

2.2. Tissue Microarray (TMA) Construction

The archive pathology specimens of the 71 patients underwent a pathology review to evaluate histological tumor characteristics and to select the representative area of the specimen to be included in the TMA. Briefly, a 3-mm core of the paraffin-embedded tissue was removed from the preselected region of each donor tissue block and then assembled into a high-density TMA. Subsequent immunohistochemical analysis of nine biomarkers and four MMR proteins was carried out on TMA blocks, as described below.

2.3. Immunohistochemistry (IHC)

Sections of 5 µm were cut from the TMA blocks then processed using the avidin–biotin–immunoperoxidase method. Immunohistochemical assays were performed on a BenchMark XT slide stainer (Ventana Medical Systems, Tucson, AZ, USA). The automated immunohistochemistry program included deparaffinization, antigen retrieval, incubation with primary antibody followed by secondary antibody, and visualization of chromogen. External tissue controls were used as positive and negative controls to check for false positive or false negative results. Negative reagent controls were performed to ensure that staining is produced by detection of the antigen by the primary antibody (Supplementary Figure S1).

For each case, monoclonal antibodies to p21 (clone DCS-60.2, 1:100; Cell Marque), cyclin D1 (clone SP4-R, ready to use; Roche Ventana), p16^{INK4a} (clone E6H4, ready to use; Roche Ventana), pRb (clone 13A10, 1:100; Leica Biosystems), CDK2 (clone E304, 1:100; Abcam), CDK4 (clone C-22, 1:100; Santa Cruz), CDK6 (clone EPR4515, 1:100; Abcam), E2F1 (clone KH95, 1:100; Santa Cruz), and Ki-67/MIB-1 (clone 30-9, ready to use; Roche Ventana) were used.

To investigate mismatch repair (MMR) protein deficiency, immunohistochemical stains for the four MMR proteins were performed on the Ventana Benchmark autostaining system. Primary antibodies for MLH1 (clone M1, ready to use; Roche Ventana), PMS2 (clone EPR3947, ready to use; Roche Ventana), MSH2 (clone G219-1129, ready to use; Roche Ventana), and MSH6 (clone 44, ready to use; Roche Ventana) were applied.

The slides were scanned on an Aperio Image Scopeslide scanner and then analyzed using Image Scope software (Aperio Technologies, Vista, CA, USA). The use of a scanner is particularly helpful for analyzing TMA slides. It provides excellent image quality while allowing for better viewing of the numerous tissue cores present in a single slide.

2.4. IHC Interpretation

A pathologist, blinded to clinical data, examined the sections with high power to determine the proportion of cells that express the markers. For each marker, the entire tumor core section was evaluated. The cut-off values used in this study were based on previously established cut-off values from immunohistochemical studies for the nine markers [27–31]. The cut-off values for tumor cell staining were defined as follows: (1) high expression of cyclin D1 if ≥50% of tumor nuclei stained; (2) high expression of p21 if ≥50% of tumor nuclei stained; (3) positive for pRb if ≥10% of tumor nuclei stained; (4) positive for p16^{INK4a} if ≥10% of tumor nuclei stained; (5) positive for CDK2 if ≥10% of tumor nuclei stained; (6) positive for CDK4 if ≥10% of tumor nuclei stained; (7) positive for CDK6 if ≥10% of tumor nuclei stained; (8) positive for E2F1 if ≥10% of tumor nuclei stained; and (9) high Ki-67 proliferative index if equal or more than 5% of tumor nuclei stained.

For the definition of the MSI screening status, loss of MMR protein expression was defined as the complete absence of nuclear staining throughout the tumor area. The lymphocytes and vascular endothelial cells served as a positive internal control. If one or more of the MMR proteins were not expressed, the result was referred to as deficient mismatch repair (dMMR).

Representative immunophenotypes for the selected marker investigated in tumor tissue are shown in Figure 1.




Figure 1. Representative images and distribution of the investigative markers. The microarray cores exhibited features of papillary carcinoma (upper panels) and follicular carcinoma (lower panels). The cores of thyroid cancer tissue showed strong expression of cyclin D1 and p21, while loss of expression of CDK4.

2.5. Statistical Methods

The basic demographics of the patients between the STC and DPC groups were compared using Fisher's exact test. To evaluate the association between biomarkers (including mismatch repair (MMR) proteins and cell-cycle regulatory proteins) and DPC status, univariate logistic regression analyses were initially performed. Moreover, those significant biomarkers in the univariate analyses were introduced into a multivariate model with backward elimination. The predicted probability of having a nonthyroid cancer derived from the multivariate model was further treated as an explanatory variable in the receiver operating characteristic (ROC) curve analysis. Univariate logistic regression analyses were stratified by tumor subtype to assess whether the relationship between each biomarker and DPC status was consistent in both subtypes. Lastly, to investigate the potential additive effect among significant biomarkers, the interaction effects among the significant biomarkers were tested. All tests were two-tailed and $p < 0.05$ was considered statistically significant. Data analyses were performed using SPSS 25 (IBM SPSS Inc., Chicago, IL, USA).

3. Results

3.1. Clinical Features of DTC Patients

To establish a prediction model, the cohort consisted of 24 patients with STC, as well as those with cancers in organs other than the thyroid (43 patients with DPC). The patient characteristics at baseline are presented in Table 1. Among the 24 SPC cases, nine patients (37.5%) were alive, while death from cancer or non-cancer-related causes was found in five patients (20.8%) during follow-up.

Table 1. Basic demographics of study cohorts.

Clinical Variable	Single Thyroid Cancer (STC)	Double Primary Cancer
	(<i>n</i> = 24) <i>n</i> (%)	(DPC) (<i>n</i> = 43) <i>n</i> (%)

Gender		
Male	3 (12.5)	9 (20.9)
Female	21 (87.5)	34 (79.1)
Age		
<50 years	14 (58.3)	15 (34.9)
≥50 years	10 (41.7)	28 (65.1)
Occurrence interval		
<6 months	NA	9 (20.9)
≥6 months	NA	34 (79.1)
Clinical outcome		
Alive	9 (37.5)	29 (67.4)
Dead	5 (20.8)	8 (18.6)
Not accessible	10 (41.7)	6 (14.0)

NA, not applicable.

Of the 43 DPC cases, nine were synchronous (interval of diagnosis <6 months), while 34 were metachronous (interval of diagnosis >6 months). The second primary malignancy included tumors from the following sites: colorectum (n = 12, 27.9%), breast (n = 11, 25.6%), head and neck (n = 6, 14.0%), lung (n = 6, 14.0%), gynecologic tract (n = 4, 9.3%), soft tissue (n = 2, 4.7%), prostate (n = 1, 2.3%), and lymphoma (n = 1, 2.3%). Up to the last date of follow-up, 29 patients (67.4%) were alive, while death from cancer or noncancer-related causes was found in eight patients (18.6%).

3.2. Expression of Mismatch Repair (MMR) Proteins and Cell-Cycle Regulatory Proteins

Immunohistochemically, dMMR was defined as complete loss of expression in one of PMS2, MLH1, MSH2, or MSH6. Of the 24 patients in the STC group, eight (33.3%) showed dMMR, with loss of expression of at least one MMR protein. The features of dMMR were identified significantly more frequently in 32 (74.4%) patients with DPC. Overall, in the abnormal IHC group, the most common deficiency identified was the simultaneous loss of expression of MLH1 and PMS2 in 23 patients, followed by isolated loss of PMS2 in 13 patients and the absence of MSH2 and MSH6 in four patients. Furthermore, all patients with DPC were further divided into groups of dMMR (32 patients) (Figure 2A) and MMR-proficient groups (intact MMR, 11 patients) (Figure 2B).

Table 2 presents the results related to the immunohistochemical expression of the markers examined. The overall positive expression rates of pRb, p16^{INK4a}, CDK2, CDK4, CDK6, and E2F1 in the STC group were 25.0%, 12.5%, 12.5%, 54.2%, 33.3%, and 33.3%, respectively. A high expression of p21 (>50%) was observed in 20.8% of cases, while a high expression of cyclin D1 (>50%) was observed in 54.2%. Most STC tissues (91.7%) revealed a low Ki-67 index (<5%).

Table 2. Univariate and multivariate analysis of logistic regression between biomarkers and the status of STC/DPC.

Variable	STC (n = 24)	DPC (n = 43)	Univariate Analysis		Multivariate Analysis	
			Crude OR (95% CI)	p Value	Adjusted OR (95% CI)	p Value
dMMR	8 (33.3)	32 (74.4)	5.82 (1.95–17.32)	0.002	10.34 (2.17–49.21)	0.003
cyclin D1	13 (54.2)	36 (83.7)	4.35 (1.39–13.61)	0.011		
p21	5 (20.8)	20 (46.5)	3.30 (1.04–10.47)	0.042		
pRb	6 (25.0)	26 (60.5)	4.59 (1.52–13.89)	0.007	62.71 (4.83–814.22)	0.002
p16 ^{INK4a}	3 (12.5)	13 (30.2)	3.03 (0.77–11.98)	0.113		
CDK2	3 (12.5)	19 (44.2)	5.54 (1.43–21.40)	0.013		
CDK4	13 (54.2)	9 (20.9)	0.22 (0.08–0.67)	0.007	0.19 (0.04–0.99)	0.049
CDK6	8 (33.3)	4 (9.3)	0.21 (0.05–0.78)	0.020	0.03 (0.002–0.44)	0.011
E2F1	8 (33.3)	15 (34.9)	1.07 (0.37–3.08)	0.898		
Ki-67	2 (8.3)	14 (32.6)	5.31 (1.09–25.83)	0.039		

STC, single thyroid cancer; DPC, double primary cancer; OR, odds ratio; CI, confidence interval.

The overall positive expression rates of pRb, p16INK4a, CDK2, CDK4, CDK6, and E2F1 in the DPC group were 60.5%, 30.2%, 44.2%, 20.9%, 9.3%, and 34.9%, respectively. A high expression of p21 (>50%) was observed in 46.5% of cases, while a high expression of cyclin D1 (>50%) was observed in 74.4%. An increase in the Ki-67 index (>5%) was observed in 32.6% of patients with DPC.




Figure 2. Expression pattern of MMR proteins. Panel (A): The tumor sample from papillary carcinoma showed dMMR status with complete loss of nuclear staining for MLH1 and PMS2. Panel (B): The tumor sample from follicular carcinoma exhibited an MMR-proficient status with intact nuclear staining for MMR proteins.

Immunoreactivities for cell-cycle regulatory proteins in the DPC group revealed that cyclin D1 and p21 were found to be more expressed than in the STC group. Positive staining for pRb and CDK2 also increased in the DPC group. In contrast, the lack of expression of CDK4 or CDK6 was found to be significantly more common in the DPC group. The DPC group showed a propensity for a high Ki-67 proliferative index.

Univariate analyses showed that the expression of the following biomarkers was correlated with the status of DPC: dMMR, cyclin D1, p21, pRb, CDK2, and Ki-67. On the other hand, univariate analyses indicated that CDK4 and CDK6 expression was correlated with STC status. The backward elimination multivariate model demonstrated that the expression of dMMR (odds ratio (OR) 10.34, 95% confidence interval (CI) 2.17–49.21) and pRb (OR 62.71, 95% CI 4.83–814.22) was significantly associated with the status of DPC. In contrast, the expression of CDK4 (OR 0.19, 95% CI 0.04–0.99) and CDK6 (OR 0.03, 95% CI 0.002–0.44) was significantly associated with the status of STC (Table 2). Representative immunohistochemical images of the investigative markers in the TMA of the DPC group are shown in Figure 3.




Figure 3. Representative immunohistochemical staining for the expression of pRb, CDK4, CDK6, and MMR proteins in the double primary cancer (DPC) group. Papillary carcinoma (left upper panel; H&E stain) showed high expression of pRb, while most cancer cells were negative for CDK4 and CDK6. Tumor tissue demonstrated deficient mismatch repair (dMMR) with loss of MLH1 and PMS2 expression.

3.3. Immunoexpression Patterns in the Papillary Carcinoma (PTC) and Follicular Carcinoma (FTC) Subtypes and the Interaction between the SPC and DPC Groups

Table 3 presents the association between biomarker expression and STC or DPC status, stratified by subtypes PTC and FTC. Most of the results were less significant due to the smaller sample size in each tumor subtype group. It is noted that all interaction effects between each biomarker and tumor subtypes were not significant, indicating that the tumor subtypes did not modify the association between each biomarker and the status of STC or DPC. In other words, the relationship between the MMR/cell-cycle regulatory proteins and the status of STC or DPC was similar between the PTC and FTC subtypes.

Table 3. The association between the biomarker and the status of STC/DPC stratified by thyroid tumor subtype.

Variable	Papillary Thyroid Cancer (PTC)			Follicular Thyroid Cancer (FTC)			<i>p</i> Interaction
	STC (<i>n</i> = 13)	DPC (<i>n</i> = 35)	OR (95% CI)	STC (<i>n</i> = 11)	DPC (<i>n</i> = 8)	OR (95% CI)	
dMMR	4 (30.8)	25 (71.4)	5.62 (1.40–22.53)	4 (36.4)	7 (87.5)	12.25 (1.08–138.99)	0.586
cyclin D1	8 (61.5)	29 (82.9)	3.02 (0.73–12.52)	5 (45.5)	7 (87.5)	8.40 (0.76–93.34)	0.474
p21	2 (15.4)	16 (45.7)	4.63 (0.89–24.04)	3 (27.3)	4 (50.0)	2.67 (0.39–18.17)	0.669
pRb	0 (0.0)	21 (60.0)	NA	6 (54.5)	5 (62.5)	1.39 (0.22–8.92)	0.998
p16 ^{INK4a}	2 (15.4)	13 (37.1)	3.25 (0.62–17.01)	1 (9.1)	0 (0.0)	NA	1.000
CDK2	0 (0.0)	17 (48.6)	NA	3 (27.3)	2 (25.0)	0.89 (0.11–7.11)	0.998
CDK4	4 (30.8)	5 (14.3)	0.38 (0.08–1.70)	9 (81.8)	4 (50.0)	0.22 (0.03–1.75)	0.689
CDK6	0 (0.0)	2 (5.7)	NA	8 (72.7)	2 (25.0)	0.13 (0.02–0.999)	0.999
E2F1	6 (46.2)	12 (34.3)	0.61 (0.17–2.22)	2 (18.2)	3 (37.5)	2.70 (0.33–21.98)	0.236
Ki-67	2 (15.4)	12 (34.3)	2.87 (0.55–15.10)	0 (0.0)	2 (25.0)	NA	0.999

STC, single thyroid cancer; DPC, double primary cancer; OR, odds ratio; CI, confidence interval; NA, not applicable.

3.4. Immunoexpression Patterns of DTC and the Interrelationship with Significant Biomarkers

The previous multivariate model identified four significant biomarkers: dMMR, pRb, CDK4, and CDK6 (Table 2). The interrelationship among the four important biomarkers

is of interest (Table 4). The results showed that the interaction effects between each significant biomarker and the other three significant biomarkers were not significant, suggesting that the association between a significant biomarker and DPC status was not modified by the other significant biomarkers. This observation implies that there was no additive effect among the major biomarkers.

Table 4. The association between the major biomarkers and the status of STC/DPC stratified by the other major biomarkers.

Variable	dMMR			MMR-Proficient			<i>p</i> Interaction
	STC (<i>n</i> = 8)	DPC (<i>n</i> = 32)	OR (95% CI)	STC (<i>n</i> = 16)	DPC (<i>n</i> = 11)	OR (95% CI)	
CDK4	3 (37.5)	7 (21.9)	0.47 (0.09–2.45)	10 (62.5)	2 (18.2)	0.13 (0.02–0.84)	0.321
CDK6	2 (25.0)	3 (9.4)	0.31 (0.04–2.28)	6 (37.5)	1 (9.1)	0.17 (0.02–1.65)	0.688
pRb	2 (25.0)	17 (53.1)	3.40 (0.59–19.46)	4 (25.0)	9 (81.8)	13.50 (2.01–90.69)	0.295
Variable	pRb = positive			pRb = negative			<i>p</i> interaction
	STC (<i>n</i> = 6)	DPC (<i>n</i> = 26)	OR (95% CI)	STC (<i>n</i> = 18)	DPC (<i>n</i> = 17)	OR (95% CI)	
dMMR	2 (33.3)	17 (65.4)	3.78 (0.58–24.75)	6 (33.3)	15 (88.2)	15.00 (2.55–88.17)	0.295
CDK4	6 (100.0)	6 (23.1)	NA	7 (38.9)	3 (17.6)	0.34 (0.07–1.61)	0.998
CDK6	5 (83.3)	4 (15.4)	0.04 (0.00–0.40)	3 (16.7)	0 (0.0)	NA	0.999
Variable	CDK4 = positive			CDK4 = negative			<i>p</i> interaction
	STC (<i>n</i> = 13)	DPC (<i>n</i> = 9)	OR (95% CI)	STC (<i>n</i> = 11)	DPC (<i>n</i> = 34)	OR (95% CI)	
dMMR	3 (23.1)	7 (77.8)	11.67 (1.53–89.12)	5 (45.5)	25 (73.5)	3.33 (0.81–13.66)	0.321
pRb	6 (46.2)	6 (66.7)	2.33 (0.40–13.61)	0 (0.0)	20 (58.8)	NA	0.998
CDK6	8 (61.5)	1 (11.1)	0.08 (0.01–0.83)	0 (0.0)	3 (8.8)	NA	0.999
Variable	CDK6 = positive			CDK6 = negative			<i>p</i> interaction
	STC (<i>n</i> = 8)	DPC (<i>n</i> = 4)	OR (95% CI)	STC (<i>n</i> = 16)	DPC (<i>n</i> = 39)	OR (95% CI)	
dMMR	2 (25.0)	3 (75.0)	9.00 (0.56–143.89)	6 (37.5)	29 (74.4)	4.83 (1.40–16.73)	0.688
pRb	5 (62.5)	4 (100.0)	NA	1 (6.3)	22 (56.4)	19.41 (2.33–161.86)	0.999
CDK4	8 (100.0)	1 (25.0)	NA	5 (31.3)	8 (20.5)	0.57 (0.15–2.11)	0.999

STC, single thyroid cancer; DPC, double primary cancer; OR, odds ratio; CI, confidence interval; NA, not applicable.

3.5. Multimarker Expression Model with Potential Implications of a Second Primary Malignancy

To identify biomarkers that could accurately determine the DPC group, a multivariate analysis of selected variables was carried out. The combined pattern of the dMMR phenotype, the expression of pRb, and the lack of CDK4 or CDK6 was examined to verify the significance in the risk evaluation. To evaluate the performance of the selected multivariate model in distinguishing the status of the DPC, a ROC analysis was performed. The result demonstrated an excellent discrimination performance with the area under the curve of 0.95 (95% CI, 0.90–0.998) (Figure 4). The predictive value for the co-occurrence of nonthyroid malignancy was also assessed. The predicted probability of DPC (ProbDPC) was equation (1):

$$\text{ProbDPC} = 1/(1 + e^{-z}) \quad (1)$$

where *e* denotes the exponential function and *z* denotes the risk score. The risk score of a predictive model of four biomarker signatures was calculated as described in the equation (2).

$$z = \beta_0 + \beta_1 \times \text{dMMR} + \beta_2 \times \text{pRb} + \beta_3 \times \text{CDK4} + \beta_4 \times \text{CDK6} \quad (2)$$

with Z equal to risk score, β_0 equal to the intercept, and β_1 to β_4 equal to each biomarker's coefficient value of each biomarker from multivariate logistic regression analysis [32,33]. In the generation dataset, $\beta_0 = -1.087$, $\beta_1 = 2.336$, $\beta_2 = 4.138$, $\beta_3 = -1.671$, and $\beta_4 = -3.578$. Patients with a predicted probability of more than 0.5 are classified as the DPC group.




Figure 4. The analysis of the receiving operating characteristics curve demonstrating the ability of the combined predictive model (dMMR phenotype, pRb expression and lack of CDK4 or CDK6) to discriminate the DPC group.

4. Discussion

In previous studies, patients with thyroid cancer have been shown to be associated with a higher risk of nonthyroid malignancies that occur in almost all organ systems [4–7,9–15,17–19,23,34]. Most of these studies focused on epidemiological trends, while other studies suggested a role for pathophysiological effects in the molecular pathogenesis of second primary malignancy [25,34]. Elucidation of common mechanisms of cancer development has important implications both in diagnostic work and in therapeutic management of thyroid cancer. To our knowledge, this study is the first TMA-based approach to investigate the expression of cell-cycle-related markers and MSI status in patients with thyroid cancer with second primary malignancies.

Detectable biomarkers can be used to guide the optimal frequency of second primary malignancy surveillance. Bunbanjerdsuk et al. reported a set of genes whose expression may serve as prognostic biomarkers for the occurrence of second cancer in head and neck squamous cell carcinomas [35]. Focusing on p16-negative cases, they showed that a multivariate logistic regression model comprising ITPR3, KMT2D, EMILIN1, and patient's age can accurately predict second cancer occurrence with 88% sensitivity and 75% specificity [35]. In a recent study, thyroid cancer cases with a heterogeneous immunohistochemically stained MMR pattern were likely to be in a state of suboptimal DNA repair capacity, presumed to have caused the co-occurrence of lung cancer [25]. According to previous observations, this technology could be useful in identifying patients with a high risk of a second cancer, based on the analysis of the expression pattern of biomarkers related to the intrinsic characteristics of the thyroid tumor.

4.1. Differences in Expression of Cell-Cycle Regulators between Individuals with and without Second Primary Malignancy

Dysregulated cell-cycle progression is one of the hallmarks of malignancy. Previous studies have reported alterations in the expression of cell-cycle regulators in various subtypes of thyroid carcinoma [36–44]. Other reports have postulated that cell-cycle regulators could serve as novel predictors of the progression and prognosis of thyroid cancer [38–43,45,46].

In the present study, we found associations among single markers and clinicopathological characteristics. Univariate analysis showed that high expression of cyclin D1 and p21 was associated with double primary malignancies ($p < 0.05$). Positivity for pRb and CDK2 (as defined in the Materials and Methods section) was also associated with DPC ($p < 0.05$). On the contrary, the expression of CDK4 and CDK6 was inversely correlated with DPC ($p < 0.05$). A similar expression pattern was observed between PTC and FTC, on the basis of the non-significant interactions. (Table 3)

Protein products of the cyclin D1 and retinoblastoma (Rb) genes play crucial roles in the regulation of the G1/S transition in the cell cycle. Cyclin D1 overexpression has been shown to be associated with aggressive behavior or adverse clinical outcomes in thyroid carcinomas [38,40–43,45,46]. Overexpression of this positive growth regulator can overwhelm the arrest mechanisms of the normal cell cycle, resulting in uncontrolled cell proliferation. On the other hand, Rb protein immunohistochemistry in malignant thyroid tumors has generated controversial results [31,47,48]. Ferenc et al. reported that overexpression of the Rb protein was found in 83.3% of follicular carcinomas [47]. On the contrary, loss of Rb immunoreactivity in IHC was observed in 82% of malignant thyroid neoplasms in another investigation of Rb expression [31]. The results of our study depict aberrant regulation of several cell-cycle proteins that could be involved in the activation or repression of cell-cycle progression in the development of second malignancies. Thus, these cell-cycle regulators represent potential candidates for new diagnostic and prognostic markers in patients with DPCs.

4.2. Possible Clinical Significance of Altered DNA Mismatch Repair Capacity in Patients with Double Primary Malignancies

Microsatellite instability (MSI) is an indicator of decreased fidelity of replication of genomic DNA, and is believed to be associated with genetic defects that promote tumorigenesis. Until now, available data on the evaluation of MMR protein expression in benign and malignant thyroid lesions have been limited [49]. Two previous reports proposed that MSI appears to be an integral part of thyroid carcinogenesis, as evidenced by the down-regulated MMR pathway and the correlation with clinical data [50,51]. In addition to prognostic relevance, Mitmaker et al. described a high frequency (63.3%) of MSI in malignant thyroid neoplasms, in agreement with our findings of cases of dMMR (59.7%) [52]. Interestingly, we found a positive correlation between dMMR phenotype and the co-occurrence of nonthyroid malignancy. In our cohort, dMMR was present in thyroid cancer specimens in all kinds of secondary primary malignancies. This finding suggests that MSI status may serve as a potential molecular predictor for high-risk patients.

4.3. A Predictive Model Based on the Four Biomarkers (dMMR, pRb, CDK4, and CDK6)

In the current study, the predictive value of immunohistochemical profiles for the co-occurrence of nonthyroid malignancy was also assessed. The significance of the dMMR-like phenotype, the expression of pRb, and the lack of CDK4 or CDK6 was then analyzed, resulting in the development of a four-biomarker signature model. To validate the performance of this model, additional two cases of STC and two cases of DPC were selected using the same criteria as described above. Immunohistochemical analysis of representative proteins was performed. Similar results were found in the four patients, that ProbDPC for two cases of STC were 0.01 and 0.06, respectively; and ProbDPC for two cases of DPC were 0.98 and 0.95, respectively. Among the data set of all 71 patients with thyroid cancer, this model has a sensitivity of 88.9% and a specificity of 69.2% for predicting the

occurrence of nonthyroid malignancy. These preliminary results are comparable to the performance of the previous model for head and neck cancer [35].

We identified four tissue-based biomarkers consisting of the dMMR phenotype and three cell-cycle regulators to predict the appearance of DPC. The association between MSI and the cell-cycle regulators cyclin D1 and p21 has been previously described, although the underlying mechanisms remain unclear [53,54]. In particular, the dMMR phenotype did not significantly modify the association between the other significant cell-cycle regulators and the DPC status. However, since these molecular pathways are not mutually exclusive and likely overlap, further analysis is essential to better understand their complex interactions.

This study had several limitations. First, this was a single institution retrospective study; therefore, the small size of the study cohort and the potential selection bias compared to the general population must be taken into account. Furthermore, the importance and robustness of the risk predictive model requires further confirmation with large prospective patient cohorts. Second, the analytical limitations of immunohistochemistry as a method may not have allowed for a precise measurement of protein expression levels. A quantitative molecular study may better integrate the immunohistochemical analyses. Selecting newly eligible cases and demonstrating convincing confirmative results in patients with DPC is necessary. Furthermore, it will be of interest to investigate and confirm the molecular pathway that leads to MMR deficiency and further elucidate the evolution of cancer development.

5. Conclusions

A comprehensive molecular analysis of DTC may help to better stratify patients for precision medicine approaches. Our results suggest that dMMR, pRb expression, and lack of CDK4 or CDK6 were significantly associated with the cooccurrence of nonthyroid malignancy. Furthermore, the combined evaluation of a four-biomarker signature model may have the most important predictive implication. The current results serve as a risk assessment for patients with thyroid cancer who develop synchronous or metachronous malignancies. Our study also permits the application of the first tissue-based screening tool for risk stratification, and its further use in active surveillance of thyroid cancer patients. Additionally, therapeutic agents targeting this pathway may play a beneficial role, and clinical studies in this setting are warranted.

Supplementary Materials: The following are available online at www.mdpi.com/article/10.3390/cancers13215486/s1, Figure S1: Antibody staining control for immunohistochemistry.

Authors Contributions: Conceptualization, C.-Y.L. and C.-J.H.; methodology, C.-Y.L. and C.-J.H.; software, C.-J.H.; validation, C.-Y.L. and C.-J.H.; formal analysis, C.-Y.L. and C.-J.H.; investigation, C.-Y.L. and C.-J.H.; resources, C.-Y.L., C.-S.H., C.-C.H., W.-C.K., H.-Y.S. and C.-J.H.; data curation, C.-Y.L., C.-S.H., C.-C.H., W.-C.K., H.-Y.S. and C.-J.H.; writing—original draft preparation, C.-Y.L. and C.-J.H.; writing—review and editing, C.-Y.L., C.-S.H., C.-C.H., W.-C.K., H.-Y.S. and C.-J.H.; visualization, C.-Y.L. and C.-J.H.; funding acquisition, C.-Y.L.; supervision, C.-J.H. and C.-S.H.; project administration, C.-Y.L. and C.-J.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the research grant from Cathay General Hospital (Grant No.: CGH-MR-A10906 (1 July 2020 to 30 June 2021)).

Institutional Review Board Statement: This study was carried out in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Cathay General Hospital, which granted exemption of informed consent (IRB No.: CGH-P108136, 28 February 2020).

Informed Consent Statement: Patient consent was waived due to anonymity and the absence of clinical characteristics.

Data Availability Statement: Data are available on request due to all institutional restrictions related to patient privacy.

Acknowledgments: The authors thank the Biobank, Cathay General Hospital, for assistance with sample preparation in this study. The authors acknowledge Alfred Hsing-Fen Lin for his statistical assistance.

Conflicts of Interest: The authors declare no conflict of interest.


References

1. Macerola, E.; Poma, A.; Vignali, P.; Basolo, A.; Ugolini, C.; Torregrossa, L.; Santini, F.; Basolo, F. Molecular Genetics of Follicular-Derived Thyroid Cancer. *Cancers* **2021**, *13*, 1139, <https://doi.org/10.3390/cancers13051139>.
2. Lloyd, R.V.; Osamura, R.Y.; Klöppel, G.; Rosai, J. WHO classification of tumours of endocrine organs, 4ed.; International Agency for Research on Cancer: Lyon, France, 2017.
3. Karaköse, M.; Çordan, I.; Can, M.; Kocabaş, M.; Kulaksızoğlu, M.; Karakurt, F.; Kulaksızoğlu, M. Incidence of second primary malignancies in patients with thyroid cancer in the Turkish population. *Turk. J. Med. Sci.* **2019**, *49*, 1529–1533, <https://doi.org/10.3906/sag-1903-104>.
4. Endo, M.; Liu, J.B.; Dougan, M.; Lee, J.S. Incidence of Second Malignancy in Patients with Papillary Thyroid Cancer from Surveillance, Epidemiology, and End Results 13 Dataset. *J. Thyroid. Res.* **2018**, *2018*, 1–11, <https://doi.org/10.1155/2018/8765369>.
5. Corrêa, N.L.; De Sá, L.V.; De Mello, R.C.R. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma. *Thyroid* **2017**, *27*, 261–270, <https://doi.org/10.1089/thy.2016.0266>.
6. Hakala, T.T.; Sand, J.A.; Jukkola, A.; Huhtala, H.S.; Metso, S.; Kellokumpu-Lehtinen, P.-L. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. *Int. J. Clin. Oncol.* **2015**, *21*, 231–239, <https://doi.org/10.1007/s10147-015-0904-6>.
7. Cho, Y.Y.; Lim, J.; Oh, C.-M.; Ryu, J.; Jung, K.-W.; Chung, J.H.; Won, Y.-J.; Kim, S.W. Elevated risks of subsequent primary malignancies in patients with thyroid cancer: A nationwide, population-based study in Korea. *Cancer* **2014**, *121*, 259–268, <https://doi.org/10.1002/cncr.29025>.
8. Hsu, C.H.; Huang, C.L.; Iqbal, U.; Nguyen, P.A.; Jian, W.S. Co-occurrence of second primary malignancy in patients with thyroid cancer. *Qjm: Int. J. Med.* **2014**, *107*, 643–648, <https://doi.org/10.1093/qjmed/hcu051>.
9. Zafon, C.; Obiols, G.; Mesa, J. Second primary cancer in patients with papillary thyroid carcinoma. *Anticancer. Res.* **2013**, *33*, 337–340.
10. Lu, C.-H.; Lee, K.-D.; Chen, P.-T.; Chen, C.-C.; Kuan, F.-C.; Huang, C.-E.; Chen, M.-F.; Chen, M.-C. Second primary malignancies following thyroid cancer: A population-based study in Taiwan. *Eur. J. Endocrinol.* **2013**, *169*, 577–585, <https://doi.org/10.1530/eje-13-0309>.
11. Lang, B.H.-H.; Wong, K.P. Risk Factors for Nonsynchronous Second Primary Malignancy and Related Death in Patients with Differentiated Thyroid Carcinoma. *Ann. Surg. Oncol.* **2011**, *18*, 3559–3565, <https://doi.org/10.1245/s10434-011-1777-1>.
12. Sawka, A.M.; Thabane, L.; Parlea, L.; Ibrahim-Zada, I.; Tsang, R.; Brierley, J.D.; Straus, S.; Ezzat, S.; Goldstein, D.P. Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis. *Thyroid* **2009**, *19*, 451–457, <https://doi.org/10.1089/thy.2008.0392>.
13. Brown, A.P.; Chen, J.; Hitchcock, Y.J.; Szabo, A.; Shrieve, D.C.; Tward, J. The Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer. *J. Clin. Endocrinol. Metab.* **2008**, *93*, 504–515, <https://doi.org/10.1210/jc.2007-1154>.
14. Verkooijen, R.B.T.; Smit, J.W.A.; Romijn, J.A.; Stokkel, M.P.M. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. *Eur. J. Endocrinol.* **2006**, *155*, 801–806, <https://doi.org/10.1530/eje.1.02300>.
15. Sandeep, T.C.; Strachan, M.W.J.; Reynolds, R.; Brewster, D.; Scélo, G.; Pukkala, E.; Hemminki, K.; Anderson, A.; Tracey, E.; Friis, S.; et al. Second Primary Cancers in Thyroid Cancer Patients: A Multinational Record Linkage Study. *J. Clin. Endocrinol. Metab.* **2006**, *91*, 1819–1825, <https://doi.org/10.1210/jc.2005-2009>.
16. Canchola, A.J.; Horn-Ross, P.L.; Purdie, D.M. Risk of Second Primary Malignancies in Women with Papillary Thyroid Cancer. *Am. J. Epidemiology* **2006**, *163*, 521–527, <https://doi.org/10.1093/aje/kwj072>.
17. Rubino, C.; De Vathaire, F.; Dottorini, M.E.; Hall, P.; Schwartz, C.; Couette, J.E.; Dondon, M.-G.; Abbas, M.T.; Langlois, C.; Schlumberger, M. Second primary malignancies in thyroid cancer patients. *Br. J. Cancer* **2003**, *89*, 1638–1644, <https://doi.org/10.1038/sj.bjc.6601319>.
18. Kim, C.; Bi, X.; Pan, D.; Chen, Y.; Carling, T.; Ma, S.; Udelsman, R.; Zhang, Y. The Risk of Second Cancers After Diagnosis of Primary Thyroid Cancer Is Elevated in Thyroid Microcarcinomas. *Thyroid* **2013**, *23*, 575–582, <https://doi.org/10.1089/thy.2011.0406>.
19. Schonfeld, S.J.; Morton, L.M.; de González, A.B.; Curtis, R.E.; Kitahara, C.M. Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000–2015. *Cancer Epidemiology* **2019**, *64*, 101664–101664, <https://doi.org/10.1016/j.canep.2019.101664>.
20. Li, S.; Yang, J.; Shen, Y.; Zhao, X.; Zhang, L.; Wang, B.; Li, P.; Wang, Y.; Yi, M.; Yang, J. Clinicopathological features, survival and risk in breast cancer survivors with thyroid cancer: An analysis of the SEER database. *BMC Public Heal.* **2019**, *19*, 1–10, <https://doi.org/10.1186/s12889-019-7947-y>.

21. Joseph, K.R.; Edirimanne, S.; Eslick, G.D. The association between breast cancer and thyroid cancer: A meta-analysis. *Breast Cancer Res. Treat.* **2015**, *152*, 173–181, <https://doi.org/10.1007/s10549-015-3456-6>.
22. Huang, J.; Walker, R.; Groome, P.G.; Shelley, W.; Mackillop, W.J. Risk of thyroid carcinoma in a female population after radiotherapy for breast carcinoma. *Cancer* **2001**, *92*, 1411–1418, doi:10.1002/1097-0142(20010915)92:6<1411::aid-cnrcr1464>3.0.co;2-9.
23. An, J.H.; Hwangbo, Y.; Ahn, H.Y.; Keam, B.; Lee, K.E.; Han, W.; Park, D.J.; Park, I.A.; Noh, D.-Y.; Youn, Y.-K.; et al. A Possible Association Between Thyroid Cancer and Breast Cancer. *Thyroid* **2015**, *25*, 1330–1338, <https://doi.org/10.1089/thy.2014.0561>.
24. Travis, L.B. The Epidemiology of Second Primary Cancers. *Cancer Epidemiology Biomarkers Prev.* **2006**, *15*, 2020–2026, <https://doi.org/10.1158/1055-9965.epi-06-0414>.
25. Fujita, S.; Masago, K. Alteration of DNA mismatch repair capacity underlying the co-occurrence of non-small-cell lung cancer and nonmedullary thyroid cancer. *Sci. Rep.* **2021**, *11*, 1–8, <https://doi.org/10.1038/s41598-021-83177-1>.
26. Dong, M.; Wei, H.; Hou, J.M.; Gao, S.; Yang, D.Z.; Lin, Z.H.; Jia, Y.; Ren, X.P.; Gao, M.H. Possible prognostic significance of p53, cyclin D1 and Ki-67 in the second primary malignancy of patients with double primary malignancies. *Int. J. Clin. Exp. Pathol.* **2014**, *7*, 3975–3983.
27. Zagouri, F.; Kotoula, V.; Kouvatsas, G.; Sotiropoulou, M.; Koletsis, T.; Gavressea, T.; Valavanis, C.; Trihia, H.; Bobos, M.; Lazaridis, G.; et al. Protein expression patterns of cell cycle regulators in operable breast cancer. *PLoS ONE* **2017**, *12*, e0180489, <https://doi.org/10.1371/journal.pone.0180489>.
28. Myong, N.-H. Cyclin D1 Overexpression, p16 Loss, and pRb Inactivation Play a Key Role in Pulmonary Carcinogenesis and have a Prognostic Implication for the Long-term Survival in Non-small Cell Lung Carcinoma Patients. *Cancer Res. Treat.* **2008**, *40*, 45–52, <https://doi.org/10.4143/crt.2008.40.2.45>.
29. Ebihara, Y.; Miyamoto, M.; Shichinohe, T.; Kawarada, Y.; Cho, Y.; Fukunaga, A.; Murakami, S.; Uehara, H.; Kaneko, H.; Hashimoto, H.; et al. Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression. *Dis. Esophagus* **2004**, *17*, 150–154, <https://doi.org/10.1111/j.1442-2050.2004.00393.x>.
30. Kjellman, P.; Wallin, G.; Höög, A.; Auer, G.; Larsson, C.; Zedenius, J. MIB-1 Index in Thyroid Tumors: A Predictor of the Clinical Course in Papillary Thyroid Carcinoma? *Thyroid* **2003**, *13*, 371–380, <https://doi.org/10.1089/105072503321669866>.
31. Anwar, F.; Emond, M.J.; Schmidt, R.A.; Hwang, H.C.; Bronner, M.P. Retinoblastoma Expression in Thyroid Neoplasms. *Mod. Pathol.* **2000**, *13*, 562–569, <https://doi.org/10.1038/modpathol.3880097>.
32. Cao, H.-H.; Zhang, S.-Y.; Shen, J.-H.; Wu, Z.-Y.; Wu, J.-Y.; Wang, S.-H.; Li, E.-M.; Xu, L.-Y. A three-protein signature and clinical outcome in esophageal squamous cell carcinoma. *Oncotarget* **2014**, *6*, 5435–5448, <https://doi.org/10.18632/oncotarget.3102>.
33. Cao, H.-H.; Zheng, C.-P.; Wang, S.-H.; Wu, J.-Y.; Shen, J.-H.; Xu, X.-E.; Fu, J.-H.; Wu, Z.-Y.; Li, E.-M.; Xu, L.-Y. A Molecular Prognostic Model Predicts Esophageal Squamous Cell Carcinoma Prognosis. *PLoS ONE* **2014**, *9*, e106007, <https://doi.org/10.1371/journal.pone.0106007>.
34. Zhang, L.; Wu, Y.; Liu, F.; Fu, L.; Tong, Z. Characteristics and survival of patients with metachronous or synchronous double primary malignancies: Breast and thyroid cancer. *Oncotarget* **2016**, *7*, 52450–52459, <https://doi.org/10.18632/oncotarget.9547>.
35. Bunbanjerdasuk, S.; Vorasan, N.; Saethang, T.; Pongrujirakorn, T.; Pangpunyakulchai, D.; Mongkonsiri, N.; Arsa, L.; Thokanit, N.; Pongsapich, W.; Anekpuritanang, T.; et al. Oncoproteomic and gene expression analyses identify prognostic biomarkers for second primary malignancy in patients with head and neck squamous cell carcinoma. *Mod. Pathol.* **2019**, *32*, 943–956, <https://doi.org/10.1038/s41379-019-0211-2>.
36. Saini, M.L.; Weynand, B.; Rahier, J.; Mourad, M.; Hamoir, M.; Marbaix, E. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential. *Diagn. Pathol.* **2015**, *10*, 32, <https://doi.org/10.1186/s13000-015-0262-8>.
37. Yang, D.; Zhang, H.; Hu, X.; Xin, S.; Duan, Z. Abnormality of p16/p38MAPK/p53/Wipl pathway in papillary thyroid cancer. *Gland. Surg.* **2012**, *1*, 33–38, <https://doi.org/10.3978/j.issn.2227-684X.2012.04.01>.
38. Lee, S.H.; Lee, J.K.; Jin, S.M.; Lee, K.C.; Sohn, J.H.; Chae, S.W.; Kim, D.H. Expression of cell-cycle regulators (cyclin D1, cyclin E, p27kip1, p57kip2) in papillary thyroid carcinoma. *Otolaryngol. Neck Surg.* **2010**, *142*, 332–337, <https://doi.org/10.1016/j.otohns.2009.10.050>.
39. Zafon, C.; Obiols, G.; Castellvi, J.; Cajal, S.R.Y.; Baena-Fustegueras, J.A.; Mesa, J. Expression of p21cip1, p27kip1, and p16INK4a Cyclin-Dependent Kinase Inhibitors in Papillary Thyroid Carcinoma: Correlation with Clinicopathological Factors. *Endocr. Pathol.* **2008**, *19*, 184–189, <https://doi.org/10.1007/s12022-008-9037-z>.
40. Pešutić-Pisac, V.; Punda, A.; Glunčić, I.; Bedeković, V.; Pranić-Kragić, A.; Kunac, N. Cyclin D1 and p27 Expression as Prognostic Factor in Papillary Carcinoma of the Thyroid: Association with Clinicopathological Parameters. *Croat. Med. J.* **2008**, *49*, 643–649, <https://doi.org/10.3325/cmj.2008.5.643>.
41. Melck, A.; Masoudi, H.; Griffith, O.; Rajput, A.; Wilkins, G.; Bugis, S.; Jones, S.; Wiseman, S.M. Cell Cycle Regulators Show Diagnostic and Prognostic Utility for Differentiated Thyroid Cancer. *Ann. Surg. Oncol.* **2007**, *14*, 3403–3411, <https://doi.org/10.1245/s10434-007-9572-8>.
42. Khoo, M.L.C.; Beasley, N.J.P.; Ezzat, S.; Freeman, J.L.; Asa, S.L. Overexpression of Cyclin D1 and Underexpression of p27 Predict Lymph Node Metastases in Papillary Thyroid Carcinoma. *J. Clin. Endocrinol. Metab.* **2002**, *87*, 1814–1818, <https://doi.org/10.1210/jcem.87.4.8353>.
43. Wang, S.; Lloyd, R.V.; Hutzler, M.J.; Safran, M.S.; Patwardhan, N.A.; Khan, A. The Role of Cell Cycle Regulatory Protein, Cyclin D1, in the Progression of Thyroid Cancer. *Mod. Pathol.* **2000**, *13*, 882–887, <https://doi.org/10.1038/modpathol.3880157>.
44. Wang, S.; Wu, J.; Savas, L.; Patwardhan, N.; Khan, A. The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis. *Hum. Pathol.* **1998**, *29*, 1304–1309, [https://doi.org/10.1016/s0046-8177\(98\)90262-3](https://doi.org/10.1016/s0046-8177(98)90262-3).

45. Temmim, L.; Ebraheem, A.K.; Baker, H.; Sinowatz, F. Cyclin D1 Protein Expression in Human Thyroid gland and Thyroid Cancer. *Anat. Histol. Embryol.* **2005**, *35*, 125–129, <https://doi.org/10.1111/j.1439-0264.2005.00648.x>.
46. Muro-Cacho, C.A.; Holt, T.; Klotch, D.; Mora, L.; Livingston, S.; Futran, N. Cyclin D1 Expression as a Prognostic Parameter in Papillary Carcinoma of the Thyroid. *Otolaryngol. Neck Surg.* **1999**, *120*, 200–207, [https://doi.org/10.1016/s0194-5998\(99\)70407-9](https://doi.org/10.1016/s0194-5998(99)70407-9).
47. Ferenc, T.; Lewinski, A.; Lange, D.; Niewiadomska, H.; Sygut, J.; Sporny, S.; Jarzab, B.; Satacińska-Los, E.; Kulig, A.; Włoch, J. Analysis of cyclin D1 and retinoblastoma protein immunoreactivity in follicular thyroid tumors. *Pol. J. Pathol.* **2005**, *56*, 27–35.
48. Holm, R.; Nesland, J.M. Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland. *J. Pathol.* **1994**, *172*, 267–272, <https://doi.org/10.1002/path.1711720307>.
49. Evren, B.; Yilmaz, S.; Karadağ, N.; Sertkaya, A.; Topaloğlu, Ö.; Kılınç, F. DNA repair proteins may differentiate papillary thyroid cancer from chronic lymphocytic thyroiditis and nodular colloidal goiter. *Sci. Rep.* **2021**, *11*, 1–8, <https://doi.org/10.1038/s41598-021-89403-0>.
50. Javid, M.; Sasanakietkul, T.; Nicolson, N.G.; Gibson, C.E.; Callender, G.G.; Korah, R.; Carling, T. DNA Mismatch Repair Deficiency Promotes Genomic Instability in a Subset of Papillary Thyroid Cancers. *World J. Surg.* **2017**, *42*, 358–366, <https://doi.org/10.1007/s00268-017-4299-6>.
51. Onda, M.; Nakamura, I.; Suzuki, S.; Takenoshita, S.; Brogren, C.H.; Stampanoni, S.; Li, D.; Rampino, N. Mi-crosatellite instability in thyroid cancer: Hot spots, clinicopathological implications, and prognostic significance. *Clin. Cancer Res.* **2001**, *7*, 3444–3449.
52. Mitmaker, E.; Alvarado, C.; Bégin, L.R.; Trifiro, M. Microsatellite Instability in Benign and Malignant Thyroid Neoplasms. *J. Surg. Res.* **2008**, *150*, 40–48, <https://doi.org/10.1016/j.jss.2007.12.760>.
53. Wangefjord, S.; Brändstedt, J.; Lindquist, K.E.; Nodin, B.; Jirstrom, K.; Eberhard, J. Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer. *Diagn. Pathol.* **2013**, *8*, 10–10, <https://doi.org/10.1186/1746-1596-8-10>.
54. Tornillo, L.; Lugli, A.; Zlobec, I.; Willi, N.; Glatz, K.; Lehmann, F.; Spichtin, H.-P.; Maurer, R.; Stoios, D.; Sauter, G.; et al. Prognostic Value of Cell Cycle and Apoptosis Regulatory Proteins in Mismatch Repair–Proficient Colorectal Cancer. *Am. J. Clin. Pathol.* **2007**, *127*, 114–123, <https://doi.org/10.1309/6rt941w1g6gdehue>.

2022 Journal Performance Data for: Cancers

 Open Access since 2009

ISSN

N/A

EISSN

2072-6694

JCR ABBREVIATION

CANCERS

ISO ABBREVIATION

Cancers

Journal Information

EDITION

Science Citation Index
Expanded (SCIE)

CATEGORY

ONCOLOGY - SCIE

LANGUAGES

English

REGION

SWITZERLAND

1ST ELECTRONIC JCR YEAR

2017

Publisher Information

PUBLISHER

MDPI

ADDRESS

ST ALBAN-ANLAGE 66,
CH-4052 BASEL,
SWITZERLAND

PUBLICATION FREQUENCY

24 issues/year

Journal's Performance

Journal Impact Factor

The Journal Impact Factor (JIF) is a journal-level metric calculated from data indexed in the Web of Science Core Collection. It should be used with careful attention to the many factors that influence citation rates, such as the volume of publication and citations characteristics of the subject area and type of journal. The Journal Impact Factor can complement expert opinion and informed peer review. In the case of academic evaluation for tenure, it is inappropriate to use a journal-level metric as a proxy measure for individual researchers, institutions, or articles. [Learn more](#)


2022 JOURNAL IMPACT FACTOR

5.2

2022 JOURNAL IMPACT FACTOR WITHOUT SELF CITATIONS

4.7

Journal Impact Factor Trend 2022



Journal Impact Factor is calculated using the following metrics






Citations in 2022 to items published in 2020 (23,660) - 2021 (28,268)		51,928		
	=		=	5.2
Number of citable items in 2020 (3,741) + 2021 (6,231)		9,972		

Journal Impact Factor without self cites is calculated using the following metrics

Citations in 2022 to items published in 2020 (23,660) + 2021 (28,268) - Self Citations in 2022 to items published in 2020 (1,976) + 2021 (3,434)		51,928 - 5,410		
	=		=	4.7
Number of citable items in 2020 (3,741) + 2021 (6,231)		9,972		

Journal Impact Factor Contributing Items

Citable Items (9,972)

TITLE	CITATION COUNT
<p>Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence</p> <p>Authors: Vaddepally, Raju K.;Kharel, Prakash;Pandey, Ramesh;Garje, Rohan;Chandra, Abhinav B.</p> <p>Volume: 12</p> <p>Accession number: WOS:000530232300214</p> <p>Document Type: Review</p>	<p>243</p> <p></p>
<p>Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer</p> <p>Authors: Akkol, Esra Kupeli;Genc, Yasin;Karpuz, Busra;Sobarzo-Sanchez, Eduardo;Capasso, Raffaele</p> <p>Volume: 12</p> <p>Accession number: WOS:000554286400001</p> <p>Document Type: Review</p>	<p>93</p> <p></p>
<p>A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis</p> <p>Authors: Sawicki, Tomasz;Ruszkowska, Monika;Danielewicz, Anna;Niedzwiedzka, Ewa;Arlukowicz, Tomasz;Przybylowicz, Katarzyna E.</p> <p>Volume: 13</p> <p>Accession number: WOS:000649866900001</p> <p>Document Type: Review</p>	<p>89</p> <p></p>
<p>Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy</p> <p>Authors: Pottier, Charles;Fresnais, Margaux;Gilon, Marie;Jerusalem, Guy;Longuespee, Remi;Sounni, Nor Eddine</p> <p>Volume: 12</p> <p>Accession number: WOS:000530232300207</p> <p>Document Type: Review</p>	<p>77</p> <p></p>
<p>Molecular Biology of Osteosarcoma</p> <p>Authors: Czarnecka, Anna M.;Synoradzki, Kamil;Firlej, Wiktoria;Bartnik, Ewa;Sobczuk, Pawel;Fiedorowicz, Michal;Grieb, Pawel;Rutkowski, Piotr</p> <p>Volume: 12</p> <p>Accession number: WOS:000579405300001</p> <p>Document Type: Review</p>	<p>74</p> <p></p>

Showing 1-5 rows of 9,972 total (use export in the relevant section to download the full table)

Journal Impact Factor Contributing Items

Citing Sources (3,648)


SOURCE NAME	COUNT
CANCERS	5,410
FRONTIERS IN ONCOLOGY	2,694
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2,375
FRONTIERS IN IMMUNOLOGY	1,333
CELLS	795
BIOMEDICINES	709
FRONTIERS IN PHARMACOLOGY	498
FRONTIERS IN GENETICS	484
SCIENTIFIC REPORTS	481
JOURNAL OF CLINICAL MEDICINE	412
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY	411
PHARMACEUTICS	410
MOLECULES	388
DIAGNOSTICS	384
SEMINARS IN CANCER BIOLOGY	302
JOURNAL OF PERSONALIZED MEDICINE	252
BMC CANCER	248
FRONTIERS IN ENDOCRINOLOGY	241
BIOMOLECULES	239
BIOMEDICINE & PHARMACOTHERAPY	231

Showing 1-20 rows of 3,648 total (use export in the relevant section to download the full table)

Journal Citation Indicator (JCI)

0.92


The Journal Citation Indicator (JCI) is the average Category Normalized Citation Impact (CNCI) of citable items (articles & reviews) published by a journal over a recent three year period. The average JCI in a category is 1. Journals with a JCI of 1.5 have 50% more citation impact than the average in that category. It may be used alongside other metrics to help you evaluate journals. [Learn more](#)



Total Citations

81,774

The total number of times that a journal has been cited by all journals included in the database in the JCR year. Citations to journals listed in JCR are compiled annually from the JCR years combined database, regardless of which JCR edition lists the journal.



Citation Distribution

The Citation Distribution shows the frequency with which items published in the year or two years prior were cited in the JCR data year (i.e., the component of the calculation of the JIF). The graph has similar functionality as the JIF Trend graph, including hover-over data descriptions for each data point, and an interactive legend where each data element's legend can be used as a toggle. You can view Articles, Reviews, or Non-Citable (other) items to the JIF numerator. [Learn more](#)

ARTICLE CITATION MEDIAN


3

REVIEW CITATION MEDIAN

5

UNLINKED CITATIONS

494



0 times cited

ARTICLES

733

REVIEWS

127

OTHER

161

Open Access (OA)

The data included in this tile summarizes the items published in the journal in the JCR data year and in the previous two years. This three-year set of published items is used to provide descriptive analysis of the content and community of the journal.[Learn more](#)

Items

TOTAL CITABLE

16,112

% OF CITABLE OA

99.36%

CITABLE

GOLD OPEN ACCESS

16,009 / 96.85%


SUBSCRIPTION OR BRONZE

103 / 0.62%

NON-CITABLE

OTHER (NON-CITABLE ITEMS)

417 / 2.52%



Citations*

TOTAL CITABLE

57,401

% OF CITABLE OA

99.22%

CITABLE

GOLD OPEN ACCESS

56,951 / 97.51%

SUBSCRIPTION OR BRONZE

450 / 0.77%


NON-CITABLE

OTHER (NON-CITABLE ITEMS)

418 / 0.72%

UNLINKED CITATIONS

585 / 1.00%



* Citations in 2022 to items published in (2020-2022)

Rank by Journal Impact factor

Journals within a category are sorted in descending order by Journal Impact Factor (JIF) resulting in the Category Ranking below. A separate rank is shown for each category in which the journal is listed in JCR. Data for the most recent year is presented at the top of the list, with other years shown in reverse chronological order. [Learn more](#)

EDITION

Science Citation Index Expanded (SCIE)

CATEGORY

ONCOLOGY

72/241

JCR YEAR	JIF RANK	QUART ILE	JIF PERCENTILE	
2022	72/241	Q2	70.3	<div><div></div></div>
2021	60/245	Q1	75.71	<div><div></div></div>
2020	51/242	Q1	79.13	<div><div></div></div>
2019	37/244	Q1	85.04	<div><div></div></div>
2018	31/230	Q1	86.74	<div><div></div></div>
2017	45/223	Q1	80.04	<div><div></div></div>

Rank by Journal Citation Indicator (JCI)

Journals within a category are sorted in descending order by Journal Citation Indicator (JCI) resulting in the Category Ranking below. A separate rank is shown for each category in which the journal is listed in JCR. Data for the most recent year is presented at the top of the list, with other years shown in reverse chronological order.[Learn more](#)

CATEGORY

ONCOLOGY

88/317

JCR YEAR	JCI RANK	QUART ILE	JCI PERCENTILE	
2022	88/317	Q2	72.40	<div><div></div></div>
2021	76/318	Q1	76.26	<div><div></div></div>
2020	78/310	Q2	75.00	<div><div></div></div>
2019	84/308	Q2	72.89	<div><div></div></div>
2018	83/302	Q2	72.68	<div><div></div></div>
2017	84/290	Q2	71.21	<div><div></div></div>


Citation network

Cited Half-life

2.3 years

The Cited Half-Life is the median age of the items in this journal that were cited in the JCR year. Half of a journal's cited items were published more recently than the cited half-life.


TOTAL NUMBER OF CITES	NON-SELF CITATIONS	SELF CITATIONS
81,774	73,612	8,162



Citing Half-life

6.2 years

The Citing Half-Life is the median age of items in other publications cited by this journal in the JCR year.



	# OF CITES FROM 2022	CUMULATIVE %	# OF CITED SOURCES
2022	466,462 citations	100.00%	16,501 sources
2021	14,592 citations	3.13%	2,474 sources
2020	47,054 citations	13.22%	4,050 sources
2019	50,520 citations	24.05%	4,188 sources
2018	42,486 citations	33.15%	3,733 sources
2017	37,851 citations	41.27%	3,555 sources
2016	33,586 citations	48.47%	3,316 sources
2015	28,862 citations	54.66%	3,081 sources
2014	25,828 citations	60.19%	2,893 sources
2013	22,190 citations	64.95%	2,694 sources
	19,570 citations	69.15%	2,447 sources
Previous years:			
143,923 citations			

Number of Cites

Citing Years

- Non-self citations: citations to the journal from the items in other sources
- Citations to items in the journal from items in the same journal
- Citations used to calculate the Impact Factor